The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes.
Open accessAbstract
We recently isolated a cDNA clone that encodes the melanocyte lineage-specific antigen glycoprotein (gp)100. Antibodies directed against gp100 are an important tool in the diagnosis of human melanoma. Since the gp100 antigen is highly expressed in melanocytic cells, we investigated whether this antigen might serve as a target for antimelanoma cytotoxic T lymphocytes (CTL). Here, we demonstrate that cytotoxic tumor-infiltrating lymphocytes (TIL) derived from a melanoma patient (TIL 1200) are directed against gp100. HLA-A2.1+ melanoma cells are lysed by TIL from this patient. In addition, murine double transfectants, expressing both HLA-A2.1 and gp100, are lysed by TIL 1200, whereas transfectants expressing only HLA-A2.1 are not susceptible to lysis. Furthermore, the HLA-A2.1+ melanoma cell line BLM, which lacks gp100 expression and is resistant to lysis, becomes susceptible after transfection of gp100 cDNA. Finally, HLA-A2.1+ normal melanocytes are lysed by TIL 1200. These data demonstrate that the melanocyte differentiation antigen gp100 can be recognized in the context of HLA-A2.1 by CTL from a melanoma patient. Gp100 may therefore constitute a useful target for specific immunotherapy against melanoma, provided that no unacceptable cytotoxicity towards normal tissue is observed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new technique for the assay of infectivity of human adenovirus 5 DNA
Graham, F. L., & van der Eb, A. J. (1973) · Virology · doi:10.1016/0042-6822(73)90341-3 · Cited by 9,451
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198812223192527 · Cited by 2,389 · cited 3×
“TILs have been shown to mediate regression of metastatic melanoma in patients treated with TILs plus IL-2 (26).”
BackgroundInfluentialSelf-citationTownsend, A. (1986) · Cell · doi:10.1016/0092-8674(86)90019-x · Cited by 1,699
Antigen Recognition by Class I-Restricted T Lymphocytes
Townsend, A., & Bodmer, H. (1989) · Annual Review of Immunology · doi:10.1146/annurev.iy.07.040189.003125 · Cited by 1,198
Brichard, V, Van Pel, A., Wölfel, T., Wölfel, C., De Plaen, E., Lethé, B., Coulie, P., & Boon, T. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.2.489 · Cited by 950
Eisinger, M., & Marko, O. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.6.2018 · Cited by 549
Parham, P., & Brodsky, F. M. (1981) · Human Immunology · doi:10.1016/0198-8859(81)90065-3 · Cited by 320
Vitiligo in patients with metastatic melanoma: A good prognostic sign
Nordlund, J. J., Kirkwood, J. M., Forget, B. M., Milton, G., Albert, D. M., & Lerner, A. B. (1983) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(83)70182-9 · Cited by 288
Sequential chemoimmunotherapy in the treatment of metastatic melanoma.
Richards, J. M., Mehta, N., Ramming, K., & Skosey, P. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.8.1338 · Cited by 257
Cited by
Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008
Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Sakaguchi, K., Appella, E., Yannelli, J. R., Adema, G. J., Miki, T., & Rosenberg, S. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.14.6458 · Cited by 914
Self-citationCoulie, P. G., Brichard, V, Van Pel, A., Wölfel, T., Schneider, J., Traversari, C., Mattei, S., De Plaen, E., Lurquin, C., Szikora, J. P., et al. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.1.35 · Cited by 903
Kawakami, Y., Eliyahu, S., Sakaguchi, K., Robbins, P. F., Rivoltini, L., Yannelli, J. R., Appella, E., & Rosenberg, S. A. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.1.347 · Cited by 862
Self-citationHuman tumor antigens recognized by T lymphocytes.
Boon, T., & van der Bruggen, P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.725 · Cited by 842
de Vries, I. J. M., Lesterhuis, W. J., Barentsz, J. O., Verdijk, P., van Krieken, J. H., Boerman, O. C., Oyen, W. J. G., Bonenkamp, J. J., Boezeman, J. B., Adema, G. J., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1154 · Cited by 821
“Finally, SPIO-labeling of dendritic cells loaded with the melanoma-specific peptide gp100:154-162 was found not to affect the peptide-specific production of interferon-γ by a gp100:154-162-specific T-cell lin”
BackgroundSelf-citationJäger, E., Chen, Y.-T., Drijfhout, J. W., Karbach, J., Ringhoffer, M., Jäger, D., Arand, M., Wada, H., Noguchi, Y., Stockert, E., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.2.265 · Cited by 725
Turning the corner on therapeutic cancer vaccines
Hollingsworth, R. E., & Jansen, K. (2019) · npj Vaccines · doi:10.1038/s41541-019-0103-y · Cited by 689
HUMAN T CELL RESPONSES AGAINST MELANOMA
Boon, T., Coulie, P. G., Eynde, B. J. V. D., & Bruggen, P. V. D. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090733 · Cited by 651
Adaptive Immune Resistance: How Cancer Protects from Immune Attack
Ribas, A. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0563 · Cited by 613
(2013) · Advances in Cancer Research · doi:10.1016/b978-0-12-407190-2.00007-1 · Cited by 594
BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes
Boël, P., Wildmann, C., Sensi, M. L., Brasseur, R., Renauld, J.-C., Coulie, P., Boon, T., & van der Bruggen, P. (1995) · Immunity · doi:10.1016/s1074-7613(95)80053-0 · Cited by 583
Van den Eynde, B., Peeters, O., De Backer, O., Gaugler, B., Lucas, S., & Boon, T. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.3.689 · Cited by 567
Valmori, D., Fonteneau, J.-F., Lizana, C. M., Gervois, N., Liénard, D., Rimoldi, D., Jongeneel, V., Jotereau, F., Cerottini, J.-C., & Romero, P. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.4.1750 · Cited by 483
Ferrone, S., & Marincola, F. M. (1995) · Immunology Today · doi:10.1016/0167-5699(95)80033-6 · Cited by 474
Exploiting the curative potential of adoptive T‐cell therapy for cancer
Hinrichs, C. S., & Rosenberg, S. A. (2014) · Immunological Reviews · doi:10.1111/imr.12132 · Cited by 466
Self-citationJäger, E., Gnjatic, S., Nagata, Y., Stockert, E., Jäger, D., Karbach, J., Neumann, A., Rieckenberg, J., Chen, Y.-T., Ritter, G., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.220413497 · Cited by 426
Coulie, P. G., Lehmann, F., Lethé, B., Herman, J., Lurquin, C., Andrawiss, M., & Boon, T. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7976 · Cited by 423
Cancer antigens: immune recognition of self and altered self.
Houghton, A. N. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.1.1 · Cited by 420
Simons, J. W., Jaffee, E. M., Weber, C. E., Levitsky, H. J., Nelson, W. G., Carducci, M. A., Lazenby, A. J., Cohen, L. K., Finn, C. C., Clift, S. M., et al. (1998) · The Journal of Urology · doi:10.1097/00005392-199802001-00032 · Cited by 410
Skipper, J. C., Hendrickson, R. C., Gulden, P. H., Brichard, V, Van Pel, A., Chen, Y., Shabanowitz, J., Wolfel, T., Slingluff, C. L., Boon, T., et al. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.2.527 · Cited by 405
Cancer vaccines based on the identification of genes encoding cancer regression antigens
Rosenberg, S. A. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)84664-6 · Cited by 386
Self-citationParacrine Cytokine Adjuvants in Cancer Immunotherapy
Pardoll, D. M. (1995) · Annual Review of Immunology · doi:10.1146/annurev.immunol.13.1.399 · Cited by 369
Lesterhuis, W. J., Punt, C. J. A., Hato, S. V., Eleveld-Trancikova, D., Jansen, B. J. H., Nierkens, S., Schreibelt, G., de Boer, A., Van Herpen, C. M. L., Kaanders, J. H., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43656 · Cited by 340
Self-citationEffector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment
Hadrup, S., Donia, M., & thor Straten, P. (2013) · Cancer Microenvironment · doi:10.1007/s12307-012-0127-6 · Cited by 310
J�ger, E., Ringhoffer, M., Dienes, H. P., Arand, M., Karbach, J., J�ger, D., Ilsemann, C., Hagedorn, M., Oesch, F., & Knuth, A. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960703)67:1<54::aid-ijc11>3.0.co;2-c · Cited by 299
Human tumor antigens for cancer vaccine development
Wang, R., & Rosenberg, S. A. (1999) · Immunological Reviews · doi:10.1111/j.1600-065x.1999.tb01331.x · Cited by 296
Self-citationMaeurer, M. J., Gollin, S. M., Martin, D., Swaney, W., Bryant, J., Castelli, C., Robbins, P., Parmiani, G., Storkus, W. J., & Lotze, M. T. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118958 · Cited by 289
Topalian, S. L., Rivoltini, L., Mancini, M., Markus, N. R., Robbins, P. F., Kawakami, Y., & Rosenberg, S. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.20.9461 · Cited by 286
Self-citationJäger, E., Ringhoffer, M., Karbach, J., Arand, M., Oesch, F., & Knuth, A. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960516)66:4<470::aid-ijc10>3.0.co;2-c · Cited by 278
DNA vaccine for cancer immunotherapy
Yang, B., Jeang, J., Yang, A., Wu, T. C., & Hung, C.-F. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/21645515.2014.980686 · Cited by 276
Wang, R. F., Robbins, P. F., Kawakami, Y., Kang, X. Q., & Rosenberg, S. A. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.2.799 · Cited by 270
Self-citationCancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects
Shafer, P., Kelly, L. M., & Hoyos, V. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.835762 · Cited by 270
A nitrite microsensor for profiling environmental biofilms
De Beer, D., Schramm, A., Santegoeds, C. M., & Kuhl, M. (1997) · Applied and Environmental Microbiology · doi:10.1128/aem.63.3.973-977.1997 · Cited by 266
Kessler, J. H., Beekman, N. J., Bres-Vloemans, S. A., Verdijk, P., van Veelen, P. A., Kloosterman-Joosten, A. M., Vissers, D. C. J., ten Bosch, G. J. A., Kester, M. G. D., Sijts, A., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.1.73 · Cited by 263
Stimulation of anti-tumor immunity by photodynamic therapy
Mroz, P., Hashmi, J. T., Huang, Y.-Y., Lange, N., & Hamblin, M. R. (2011) · Expert Review of Clinical Immunology · doi:10.1586/eci.10.81 · Cited by 261
Cancer/testis‐associated genes: Identification, expression profile, and putative function
Zendman, A. J. W., Ruiter, D. J., & Van Muijen, G. N. P. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10215 · Cited by 255
Wang, R. F., Parkhurst, M. R., Kawakami, Y., Robbins, P. F., & Rosenberg, S. A. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.1131 · Cited by 255
Self-citationThe Silver locus product Pmel17/gp100/Silv/ME20: controversial in name and in function
Theos, A. C., Truschel, S. T., Raposo, G., & Marks, M. S. (2005) · Pigment Cell Research · doi:10.1111/j.1600-0749.2005.00269.x · Cited by 224
MHC Class I Antigens and Immune Surveillance in Transformed Cells
Aptsiauri, N., Cabrera, T., Garcia‐Lora, A., Lopez‐Nevot, M. A., Ruiz‐Cabello, F., & Garrido, F. (2007) · International Review of Cytology · doi:10.1016/s0074-7696(07)56005-5 · Cited by 145
Evolution of Cancer Vaccines—Challenges, Achievements, and Future Directions
Tay, B. Q., Wright, Q., Ladwa, R., Perry, C., Leggatt, G., Simpson, F., Wells, J. W., Panizza, B. J., Frazer, I. H., & Cruz, J. L. G. (2021) · Vaccines · doi:10.3390/vaccines9050535 · Cited by 76
Metadata
- Authors
- Bakker, A. B., Schreurs, M. W., de Boer, A. J., Kawakami, Y., Rosenberg, S. A., Adema, G. J., & Figdor, C. G.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1994-03-01
- Volume
- 179
- Issue
- 3
- Pages
- 1005-1009
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2008494452
- Cited by
- 589
- References
- 21
- FWCI
- 19.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.